Managing Director & Partner
Joshua Kellar leads Boston Consulting Group's Global Scientist Network of over 500 MDs and PhDs and co-leads BCG's medical response to COVID-19 (including diagnostics, therapies, vaccines, and health system response). Josh focuses on innovation in health care that drives public good. His particular areas of focus are: digital, scientific, and payment-model based innovation. He works closely with integrated health systems, private investors, and biopharmaceutical and medical technology companies.
Before joining the firm, Josh was a postdoctoral fellow in oncology at Northwestern University.
How can health systems deliver patient-centered, value-based care worldwide? To answer this question, BCG experts Stefan Larsson, Jennifer Clawson, and Josh Kellar (with Robert Howard) examine powerful case studies of public and private innovators in high- and low-income countries alike. The Patient Priority is designed as a practical step-by-step guide for clinicians, payers, and policymakers to put these ideas into action.
Protecting the health-vulnerable population first can shave months off a country’s reopening.
With the right strategic thinking, health care systems will finally succeed in delivering the benefits that consumers have come to expect from other industries.
Governments cannot let the most vulnerable be the least protected again. Countries, regions, and states can still get the rollout right through science, hard work, and vigilance.
A big gap in our overall testing capability remains unfilled—the ability to tell people quickly and reliably if they have been infected.
To realize the transformative potential of big data, organizations must ensure that patient data is used safely and ethically.
As countries begin to lift restrictions on social interaction, effective deployment of contact tracing will be a critical weapon in the battle to contain COVID-19. But it won’t succeed without privacy safeguards and the right incentives for adoption.
A new consumer sentiment survey reveals concrete steps that health care providers can take to accelerate patients’ return.
A 12- to 18-month timeline assumes that a vaccine progresses through all the various stages of testing without encountering significant issues.
There are positive signs of potential benefits across multiple drug classes and candidates.
Innovative practices in response to the crisis suggest an emerging model for fighting any disease and managing populations’ health.